Literature DB >> 34921352

Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications.

Robert J H Miller1, Nowell Fine2.   

Abstract

Entities:  

Year:  2021        PMID： 34921352     DOI： 10.1007/s12350-021-02880-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  3 in total

1.  Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis.

Authors:  Golnaz Roshankar; Geneva C White; Sebastien Cadet; Nowell M Fine; Denise Chan; James A White; Victor Jimenez-Zepeda; Piotr J Slomka; Robert J H Miller
Journal:  J Nucl Cardiol       Date:  2021-10-03       Impact factor: 3.872

2.  Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT.

Authors:  Chao Ren; Jingyun Ren; Zhuang Tian; Yanrong Du; Zhixin Hao; Zongyao Zhang; Wei Fang; Fang Li; Shuyang Zhang; Bailing Hsu; Li Huo
Journal:  EJNMMI Phys       Date:  2021-01-07
  3 in total
  2 in total

1.  "Global" cardiac atherosclerotic burden assessed by artificial intelligence-based versus manual segmentation in 18F-sodium fluoride PET/CT scans: Head-to-head comparison.

Authors:  Reza Piri; Lars Edenbrandt; Måns Larsson; Olof Enqvist; Sofie Skovrup; Kasper Karmark Iversen; Babak Saboury; Abass Alavi; Oke Gerke; Poul Flemming Høilund-Carlsen
Journal:  J Nucl Cardiol       Date:  2021-08-12       Impact factor: 3.872

2.  Quantitative SPECT in PYP imaging: Ready for prime time or too early to tell?

Authors:  Shivda Pandey
Journal:  J Nucl Cardiol       Date:  2021-12-10       Impact factor: 3.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.